Dow Jones

40 211,72

0,53%

DAX

Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

S'inscrire

Accueil
Investir
Actions
Etats-Unis
NASDAQ
Allos Therapeutics, Inc. (MM) (ALTH)
Allos Therapeutics, Inc. (MM) (ALTH) Actualités

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:NASDAQ:ALTH

<< Précédent 4 5 6 7 8 9 10 11 12 13 14

Date	Heure	Source	Titre	Symbole	Société
04/05/2004	00h04	PR Newswire (US)	FDA Advisory Committee Does Not Recommend Approval of RSR13 as Adjunctive Therapy for the Treatment of Brain Metastases Originat	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
30/04/2004	23h30	PR Newswire (US)	Allos to Discuss ODAC Panel Recommendation on Monday May 3, 2004	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
12/03/2004	20h54	PR Newswire (US)	Allos NDA to be Reviewed by FDA Advisory Committee	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
11/03/2004	21h17	PR Newswire (US)	American Stock Exchange to Trade Options on Three Securities	NASDAQ:ALTH
06/03/2004	00h59	PR Newswire (US)	Allos Therapeutics Files Shelf Registration Statement	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
12/02/2004	13h45	PR Newswire (US)	Reminder - Allos Therapeutics Management Conference Call	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
12/02/2004	13h00	PR Newswire (US)	Allos Begins Phase 3 Study of RSR13 in Women With Brain Metastases From Breast Cancer	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
12/02/2004	12h00	PR Newswire (US)	Allos Therapeutics Reports Fourth Quarter and Year-End 2003 Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
04/12/2003	12h00	PR Newswire (US)	Allos Completes New Drug Application for Novel Treatment for Patients With Breast Cancer and Brain Metastases	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/12/2003	23h30	PR Newswire (US)	Arizona Cancer Center Investigator Presents Positive Survival and Quality of Life Data From RSR13 Phase 3 Study	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
24/11/2003	13h00	PR Newswire (US)	Allos Therapeutics Announces RSR13 Phase 3 Results in Patients With Breast Cancer and Brain Metastases Will Be Highlighted at th	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
20/11/2003	23h24	PR Newswire (US)	Allos Therapeutics Completes $12 Million Private Placement	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
18/11/2003	18h30	PR Newswire (US)	Allos Therapeutics Announces Presentation of Phase 1 Results of PDX in Patients With Advanced Non-Small Cell Lung Cancer	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
17/11/2003	12h00	PR Newswire (US)	Allos Therapeutics Announces Presentation of RSR13 Phase 3 Results in Brain Metastases at the Eighth Annual Meeting of the Socie	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
15/11/2003	20h00	PR Newswire (US)	RSR13 Investigator Presented With National Tumor Foundation Research Award At Society for Neuro-Oncology Annual Meeting	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
06/11/2003	13h45	PR Newswire (US)	Reminder - Webcast Alert: Allos Therapeutics, Inc. Announces Third Quarter 2003 Financial Results Conference Call on the Web	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
06/11/2003	12h00	PR Newswire (US)	Allos Therapeutics Reports Third Quarter 2003 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
31/10/2003	13h45	PR Newswire (US)	Webcast Alert: Allos Therapeutics, Inc. Announces Third Quarter 2003 Financial Results Conference Call on the Web	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)